兴齐眼药: 关于2025年度向特定对象发行股票摊薄即期回报的风险提示及填补回报措施和相关主体承诺的公告

Core Viewpoint - The company plans to issue shares to specific investors in 2025, raising up to 850 million yuan, which may dilute immediate returns for existing shareholders [2][3][8]. Group 1: Financial Impact of Share Issuance - The total number of shares before the issuance is 245,348,945, and the maximum number of shares to be issued is 73,604,683, which represents up to 30% of the pre-issuance total [2][3][6]. - The projected net profit for 2025, assuming no growth, is estimated to remain at 347,542,460 yuan, leading to a basic earnings per share (EPS) of 1.38 yuan post-issuance [6][7]. - Under three scenarios of net profit growth (0%, 10%, and 20%), the diluted EPS and return on equity (ROE) will decrease post-issuance, indicating a potential dilution of shareholder returns [6][7][8]. Group 2: Necessity and Reasonableness of the Issuance - The funds raised will be allocated to the construction of a research and development center and to supplement working capital, aligning with the company's strategic direction and industry trends [9][10]. - The issuance is deemed necessary to enhance the company's R&D capabilities and improve its financial structure, which is expected to strengthen its competitive position in the market [9][10][11]. Group 3: Measures to Mitigate Dilution of Returns - The company plans to implement measures to counteract the dilution of immediate returns, including enhancing core business operations and improving fund management [9][11]. - Commitments from major stakeholders, including the controlling shareholder and management, have been made to ensure the effectiveness of these measures and to protect shareholder interests [12][13].